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Spinal muscular atrophy 
phenotype is ameliorated in 
human motor neurons by SMN 
increase via different novel RNA 
therapeutic approaches
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Spinal muscular atrophy (SMA) is a primary genetic cause of infant mortality due to mutations in the 
Survival Motor Neuron (SMN) 1 gene. No cure is available. Antisense oligonucleotides (ASOs) aimed 
at increasing SMN levels from the paralogous SMN2 gene represent a possible therapeutic strategy. 
Here, we tested in SMA human induced pluripotent stem cells (iPSCs) and iPSC-differentiated motor 
neurons, three different RNA approaches based on morpholino antisense targeting of the ISSN-1, 
exon-specific U1 small nuclear RNA (ExSpeU1), and Transcription Activator-Like Effector-Transcription 
Factor (TALE-TF). All strategies act modulating SMN2 RNA: ASO affects exon 7 splicing, TALE-TF 
increase SMN2 RNA acting on the promoter, while ExSpeU1 improves pre-mRNA processing. 
These approaches induced up-regulation of full-length SMN mRNA and differentially affected the 
Delta-7 isoform: ASO reduced this isoform, while ExSpeU1 and TALE-TF increased it. All approaches 
upregulate the SMN protein and significantly improve the in vitro SMA motor neurons survival. Thus, 
these findings demonstrate that therapeutic tools that act on SMN2 RNA are able to rescue the SMA 
disease phenotype. Our data confirm the feasibility of SMA iPSCs as in vitro disease models and 
we propose novel RNA approaches as potential therapeutic strategies for treating SMA and other 
genetic neurological disorders.
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by lower 
alpha motor neuron (MN) degeneration, which results in progressive muscle weakness, paralysis, and 
often death1. SMA is the primary genetic cause of infantile mortality, with an estimated incidence of 1 in 
6,000 to 10,000 live births and a carrier frequency of 1:40 to 1:602. The spectrum of SMA disease severity 
comprises four clinical subtypes (SMA types I-IV) based on the age of onset, highest motor function 
achieved, and age at death3.
SMA is caused by mutations in the Survival Motor Neuron 1 (SMN1) gene on chromosome 5q, which 
encodes the ubiquitously expressed SMN protein4. SMN is involved in the biogenesis of small nuclear 
ribonucleoproteins (snRNPs) and in mRNA splicing. However, the exact role of SMN protein in the 
pathogenesis of SMA and the reasons for the selective loss of MNs remain largely unknown5.
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On the same chromosome, the human genome harbors a second, almost identical copy of SMN1, 
termed SMN2. The two genes differ by only a few nucleotides, one of which is a single-nucleotide, 
C-to-T transition that leads to the alternative splicing and exclusion of exon 7 from the SMN2 tran-
script6. The majority of the expressed protein is unstable and non-functional; it is rapidly degraded by 
cellular enzymatic activity owing to inefficient oligomerization7. However, 15% of SMN protein derived 
from SMN2 is a full-length functional protein that provides partial disease modification8. Indeed, an 
inverse correlation is observed between SMN2 copy number and the severity of the disease phenotype9. 
Several SMN2-targeted therapeutic strategies have been developed that aim to upregulate SMN protein 
expression3. Antisense oligonucleotides, including phosphothiorate oligonucleotides or morpholino oli-
gonucleotides (MOs), can effectively modify the RNA splicing of SMN2, providing a possible therapeutic 
strategy3. We and other groups have demonstrated that oligonucleotides targeting the ISS-N1 region 
of SMN2 are able to effectively upregulate SMN in in vivo SMA rodent models, rescuing their phe-
notype6,10–12. Phase III clinical trials with phophothiorate-modified oligonucleotides sponsored by ISIS 
Pharmaceutical are ongoing in SMA patients (www.clinicaltrial.gov).
The SMA phenotype can be reproduced to some extent in vivo in several transgenic mouse models 
that have been made available over the years. However, given the fundamental biological differences of 
the murine genome, including the lack of SMN2, there is no equivalent animal model that is a perfect 
match for the human disease. This situation represents a fundamental limit regarding the translation of 
preclinical therapeutic studies into human clinical trials. The possibility of generating iPSCs from human 
adult fibroblasts has provided unprecedented opportunities for modeling neurological diseases, including 
SMA13. In our previous work, we generated iPSC lines derived from two individuals affected by SMA 
type I, and observed the reduced survival of iPSC-derived MNs in long-term culture14. Data from our 
experiments also proved to be consistent with the work of other groups13,15,16.
In the present study, we expanded the number of our SMA cell lines by generating novel iPSCs with 
viral and non-viral protocols in order to test the reproducibility of our previous experiment. Indeed, we 
demonstrated that cell survival in long-term culture is universally reduced in MNs derived from all iPSC 
lines. Furthermore, we showed that the disease phenotype observed in SMA MN cultures was rescued 
by the increase of SMN via oligonucleotides with morpholino (MO) chemistry targeting the ISS-N1 
region of SMN2. We also tested the ability of an exon-specific U1 small nuclear RNA (ExSpeU1s) to 
rescue SMN2 pre-mRNA splicing. ExSpe U1s are modified U1 snRNAs that interacting with intronic 
sequences downstream of the 5′ splice site (ss) through complementarity, improves exon skipping caused 
by different types of mutation. This method was recently proven to correct splicing defects in different 
human diseases17,18. Here, we demonstrated that ExSpe U1 promoted significant correction of endoge-
nous SMN2 Exon 7 splicing and resulted in the restoration of the corresponding SMN protein levels in 
SMA iPSCs and iPSC MNs.
Transcription activator-like effector (TALE) proteins are emerging as a novel tool for targeting spe-
cific DNA sequences in the field of transcriptional modulation and genome editing19. In particular, 
TALEs fused to transcription factors (TALE-TFs) may be employed to specifically induce the expression 
of a gene of interest19. Here, for the first time, we successfully tested the potential therapeutic use of 
TALE-TFs targeting the SMN2 promoter with the aim of inducing the expression of the endogenous 
SMN2 gene at a therapeutic level.
Results
Generation of iPSC lines from SMA patients. In an earlier work, we generated iPSCs from fibro-
blasts from two patients with type 1 spinal muscular atrophy (SMA1)14. In order to reproduce and further 
characterize the SMA phenotype in other cell lines, we generated iPSC lines from two SMA patients with 
a viral protocol (using retrovirus)20 and with a non-viral method from one SMA patient as described 
previously14 (Fig. 1A, Fig. S1, and Table 1).
Regarding the viral protocol, human iPSCs were generated with the classical Yamanaka protocol20 by 
transducing human fibroblasts with retroviruses encoding the four transcription factors (OCT4, SOX2, 
KLF4, and c-MYC) that have been demonstrated to reprogram somatic cells to pluripotency. The cells 
were isolated using morphological selection criteria without the use of fluorescent marker or drug selec-
tion. In human pluripotent stem cell culture conditions, the morphology of human iPSCs is similar 
to that of human ESCs. The cells (> 3 clones per patient) express the pluripotency markers NANOG, 
SSEA3, and TRA-60-1, and show strong endogenous alkaline phosphatase activity (Fig. 1B).
We also generated cell lines from a third patient through a single nucleofection with episomally 
expressed oriP/EBNA1-based pluripotency factors (OCT4, SOX2, NANOG, LIN28, c-MYC, and KLF4), as 
described14, (Fig. S1A, B). Clones were generated and characterized for pluripotency markers, including 
expression of cell surface (SSEA3, SSEA4, TRA-1-60, and TRA-1-81) and nuclear (OCT4, NANOG, and 
SOX2) proteins (Fig. S1C). The SMA and wild-type (wt) lines used in this work are described in Table 1.
SMN upregulation in SMA-iPSCs using MOs. Previous works by us and others have described 
the possibility of upregulating SMN levels by modifying SMN2 splicing with antisense oligonucleotides 
(ASOs)6,10–12. MO is a particular type of ASO; its modified backbone imparts greater safety, stability, 
and efficacy, which allowed us to rescue the SMA phenotype in transgenic mice11. We decided to test 
the MO sequence (MO-10-34), already proven by us to be effective in in vivo SMA models, in vitro in 
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SMA patient-specific iPSCs11. MO-10-34 is able to block intron splicing silencer (ISS-N1), and allows the 
inclusion of exon 7 in the SMN2 transcript, thus converting SMN2 into a functional SMN1-like gene able 
to produce a sufficient amount of functional SMN protein (Fig. 2A). After treating iPSCs with MO-10-
34, we performed immunocytochemistry (Fig.  2B), western blotting (after 7 days) (Fig.  2C), and real 
time analyses (72 hours) (Fig. 2D). We observed a significant increase in the expression of SMN protein 
(1,6 fold increase vs. scramble-treated cells used as negative controls; P < 0.01), along with a greater 
representation of nuclear gems (44 ± 7 treated cells vs. 9 ± 3 scramble-treated cells used as negative 
controls, P < 0.01 ANOVA; Fig.  2E). Gems are specific protein-nuclear complexes that form when the 
SMN protein is present. They are essential for protein splicing and are absent in SMA cells. The rescue 
of gems in MO-treated SMA cells was remarkable.
Treatment of spinal motor neurons with MO-10-34. We investigated whether an increase in SMN 
level using MO-10-34 could rescue the SMA phenotype in differentiated iPSC-MNs. Generation of spinal 
MNs from all iPSC lines was achieved using a multistage differentiation protocol previously developed 
for human iPSCs using RA and SHH (Fig. 3A)14. After 4–5 weeks under differentiation conditions, cells 
Figure 1. Generation and characterization of SMA iPSC lines. (A) Scheme of the iPSC generation 
protocol. Human iPSCs were generated by transducing human fibroblasts with retroviruses that encoded 
four reprogramming transcription factors (OCT4, SOX2, KLF4, and c-MYC). (B) When cultured under 
standard human ESC culture conditions, the morphology of human iPSCs is identical to that of human 
ESCs. The cells also express the pluripotency markers NANOG, SSEA3, and TRA-60-1, and demonstrate 
strong endogenous alkaline phosphatase activity (AP). Contrast phase images show the typical ESC 
morphology. Scale bar: 75 μ m.
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were generated that expressed MN-specific transcription factors, such as spinal cord progenitor mark-
ers (e.g. HB9, ISLET1, and OLIG2) and pan-neuronal markers (e.g. TuJ1, Neurofilament, and MAP2). 
The majority of these HB9/ISLET1-positive neurons expressed Choline Acetyl Transferase (ChAT) and 
were positive for the MN marker SMI-32, demonstrating a MN phenotype (Fig.  3B). The in vitro dif-
ferentiation protocol yielded a mixed cell population that included non-MN cells. Given the limited 
availability of surface markers to isolate MNs and purify them further, we applied a physical strategy 
based on gradient centrifugation. After cells were selected using this method, immunocytochemistry 
analysis showed that the percentage of ChAT + SMI32 + cells was 78.2 ± 8.8% for cells derived from 
wt-iPSCs, 73.3 ± 6.9% for cells derived from untreated SMA-iPSCs, and 74.1 ± 6.1% for cells derived 
from MO-treated SMA-iPSCs. Astrocytic cells were quantified. Less than 1% of cells differentiated from 
iPSCs expressed the astrocyte marker GFAP. Because SMA iPSC-derived MNs exhibit reduced survival in 
long-term culture, we increased the cell culture time (Fig. 3B). At 10 weeks, we observed a reduction of 
MNs in the untreated SMA-iPSC cultures compared with wt-iPSCs with respect to cell count (P < 0.001; 
Fig. 3C). SMA-iPSC MNs that were treated with MO-10-34 exhibited increased survival compared with 
MNs derived from SMA-iPSCs-MNs treated with control vector (P < 0.001, ANOVA; Fig. 3C).
The quantification of nuclear gems demonstrated that their number was increased in MNs derived 
from treated versus untreated SMA-iPSCs (Fig. 3D). We concluded that cellular damage in human 
SMA-MN caused by the defective SMN1 gene can be rescued by SMN2 gene modulation using MO.
SMN upregulation in SMA-iPSCs using ExSpeU1 targeting SMN2. To evaluate the therapeu-
tic effect of ExSpeU1s on SMA-iPSCs and any corresponding SMN expression changes, we transduced 
SMA-iPSCs with vector containing ExSpeU1 that target the intronic sequences downstream the splice 
donor site of intron 7 in SMN2 (Fig.  4A). We previously described sequence encoding ExSpeU1s for 
SMN2 (sm17)18. After treating iPSCs with ExSpeU1, we performed immunocytochemistry, western blot-
ting, and real-time analyses (Fig.  4B,C). We observed a significant increase in the expression of SMN 
protein (> 1.5-fold increase; P < 0.01 vs. cells treated with control vector used as negative controls). We 
conclude that ExSpeU1s effectively increases SMN protein expression in SMA stem cells.
We investigated whether an increase in SMN level using ExSpeU1 could rescue the SMA phenotype 
in MN in vitro. We differentiated ExSpeU1-corrected iPSCs into MNs and enriched them with cen-
trifugation, as described for the MO experiments. At 10 weeks, we observed more MNs in the treated 
SMA-iPSC-MN cultures than in the control vector-treated cells (P < 0.001) (Fig.  4D,E). We detected a 
greater representation of nuclear gems (34 ± 9 treated cells vs. 10 ± 5 negative control cells, P < 0.01, 
ANOVA) (Fig. 4F). We concluded that MN degeneration in SMA could also be rescued by SMN2 gene 
modulation using ExSpeU1.
SMN upregulation in SMA iPSCs using TALE-TFs. TALE proteins are emerging as a novel tool 
for targeting specific DNA sequences in the field of transcriptional modulation and genome editing. In 
particular, TALE-TFs may be employed to specifically induce the expression of a gene of interest19. We 
tested the potential therapeutic use of TALE-TFs targeting SMN2 promoter with the aim of inducing 
endogenous SMN2 gene expression in in vitro models of SMA (Fig. 5A). We transfected SMA iPSCs with 
iPSC line Diagnosis Mutations SMN1 Sex
Age 
(Months)
Reprogramming 
strategy Reference
SMA 1.1 SMA1 EX7-8DEL Male 3 Non-viral 6 factors: OSKM+ LN
Corti et al. 
2012
SMA 2.1 SMAI EX7-8DEL Male 2 Non-viral 6 factors: OSKM+ LN
Corti et al., 
2012
SMA 3.1 SMAI EX7-8DEL Male 3 Non-viral 6 factors: OSKM+ LN This report
SMA 4.1 SMAI EX7-8DEL Male 3 Viral 4 factors: OSKM This report
SMA 5.1 SMA EX7-8DEL Female 3 Viral 4 factors: OSKM This report
HET Father of patient 1 Heterozygous EX7-8DEL Male N/Avail Non-viral 6 factors: OSKM+ LN
Corti et al. 
2012
19.9 Healthy Donor – Male Newborn Non-viral 6 factors: OSKM+ LN Yu et al. 2009
CTR AC 1.1 Healthy Donor – Female 24 Non-viral 6 factors: OSKM+ LN
Simone et al. 
2014
CTR AC 1.2 Healthy Donor – Female 24 Non-viral 6 factors: OSKM+ LN
Simone et al. 
2014
CTR AC 13 Healthy Donor – Female 24 Non-viral 6 factors: OSKM+ LN
Simone et al. 
2014
Table 1.  Characteristics of human fibroblast-derived SMA induced pluripotent stem cell (iPSC) lines 
and controls. N/Avail, Not available.
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12 combinations of five TALE-TF constructs (1− 5, Table  2), each specifically targeting different DNA 
sequences within the human SMN2 promoter. Quantitative RT-PCR analysis of SMA iPSCs transfected 
with TALE-TFs compared with untreated SMA iPSCs yielded results consistent with an increase in SMN 
expression for combinations 1 + 3 + 5 (FL SMN: >2-fold; SMNΔ 7: > 3.5-fold), 2 + 3 + 5 (FL SMN and 
SMNΔ 7: > 1.5-fold), 2 + 3 + 4 (SMNΔ 7: ~1.5-fold) and 2 + 4 + 5 (SMNΔ 7: > 1.1-fold) (P < 0.01 for all). 
From this preliminary screen, we selected the TALE-TF combinations that had most successfully upregu-
lated SMN (3 + 5, 1 + 3 + 5, and 2 + 3 + 5) and re-tested them in SMA iPSC lines. Quantitative RT-PCR 
analysis confirmed our previous results regarding the transcriptional activation of endogenous SMN2 in 
transfected SMA iPSCs, and showed that TALE-TFs 1 + 3 + 5 were the most effective of all TALE-TF 
combinations employed in our experiment: respective increases in the expression of full-length SMN and 
SMN lacking exon 7 (SMNΔ 7 isoform) by > 3-fold and > 2.5-fold were observed in SMA iPSCs treated 
with this combination (Fig. 5B). Accordingly, immunocytochemical analysis detected greater expression 
of SMN in SMA iPSCs transfected with TALE-TF combination 1 + 3 + 5 than in mock-transfected SMA 
iPSCs (p < 0.01, ANOVA), as documented by a diffuse fluorescent signal (Fig. 5C). Fluorescence signify-
ing the binding of anti-SMN antibodies to the targeted protein was significantly brighter in treated cells 
(p < 0.01, ANOVA), indicating the transcriptional activation of endogenous SMN2 (Fig. 5D). These data 
suggest that specific TALE-TFs targeting the SMN2 promoter upregulated SMN expression in our in 
vitro iPSC model of SMA. Therefore, TALE-TF technology may be successfully employed to treat SMA 
pathology and deserves further investigation.
Figure 2. MO-10-34 increases SMN in SMA iPSCs. (A) Schematic representation of the PMO-10-34 
sequence and its interaction with the ISS-N1 target of SMN2 pre-mRNA. (B) After treating iPSCs with 
PMO-10-34, immunocytochemical analysis revealed a greater representation of nuclear gems (green) in MO-
treated SMA iPSCs than in scrambled SMA-treated iPSCs. Nuclei are labeled with DAPI (blue). Western blot 
(C) and quantitative RT-PCR (D) analyses demonstrated a significant > 2-fold increase in the expression 
of full-length SMN protein in treated SMA iPSCs compared with scrambled SMA-treated iPSCs (*p < 0.01; 
ANOVA). Values represent means ± s.e.m. from five independent experiments performed in triplicate. (E) 
Gems quantification confirmed the increase in the number of gems in MO-treated vs. scramble-treated 
cells. Gems counts in wild-type (WT) and heterozygous (HET) cells are shown for comparison (*p < 0.01, 
ANOVA). Scale bar: 75 μ m. Values represent means ± s.e.m. from five independent experiments performed 
in triplicate.
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Comparison of SMN full-length and Delta-7 upregulation in SMA iPSCs using the three differ-
ent approaches. We demonstrated that all the three approaches induced up-regulation of full-length 
SMN mRNA in line with their mechanism. Here we want to compare how the various approaches dif-
ferently affect the proportion of full-length and Delta-7 isoform. In fact, we demonstrated by real time 
RT PCR and quantitative RT-PCR analyses that the three strategies, while upregulating full-length, dif-
ferentially affect the Delta-7 isoform: ASO reduced this isoform, while ExSpeU1 and TALE-TF increased 
it (Fig. S2).
Discussion
Despite promising therapeutic strategies in development, SMA remains a devastating neuromuscular 
disease without any effective treatment. The cell type that is primarily affected in SMA is fundamentally 
inaccessible, and the absence of in vivo models that naturally develop SMA or harbor SMN2 represents 
an obstacle to therapeutic developments3. iPSCs and their differentiated cells represent a useful in vitro 
model for the elucidation of the molecular and pathological processes involved in SMA, and for screen-
ing novel therapeutic approaches13.
In this study, we derived human iPSCs from SMA patients using viral and oriP/EBNA1-based 
transgene-free vectors, expanding our patients’ specific cell library. The use of a non-viral method 
allowed us to obtain iPSCs without genetic modification. The described use of SMA iPSC-derived MNs 
Figure 3. MO-10-34 ameliorates the SMA phenotype in iPSC-MNs, increasing cell survival in long-
term cultures. (A) Schematic differentiation protocol detailing the differentiation of iPSCs into motor 
neurons (MNs). (B) iPSCs (wild-type (WT), treated (TR)-SMA iPSCs, and scramble SMA-treated iPSCs) 
differentiated into MNs, and expressed typical MN markers: SMI32-positive (green) and ChAT-positive 
(red). MNs appear yellow, representing the merging of red and green colors. Nuclei are labeled with 
DAPI (blue). SMA-MNs derived from scramble SMA-treated iPSCs appeared smaller and more sparse 
than MNs derived from WT-iPSCs. Notably, MNs derived from MO-treated iPSCs presented a rescue of 
cell density and size in culture, similar to MNs derived from WT iPSCs. (C) Quantification of MNs at 
week 10 after differentiation from iPSCs showed increased MN survival of TR SMA iPSC–derived MNs 
compared with scramble SMA iPSC–derived MNs (*p < 0.001, ANOVA). Values represent means ± s.e.m. 
from five independent experiments performed in triplicate. (D) MO-treated iPSC-derived MNs presented 
a significantly increased number of gems relative to MNs derived from scramble-treated SMA iPSCs. Gem 
counts in wild-type (WT) and heterozygous (HET) cells are shown for comparison (*p < 0.01, ANOVA). 
Values represent means ± s.e.m. from five independent experiments performed in triplicate. Scale bar: 75 μ m.
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Figure 4. ExSpeU1 snRNA increases SMN expression in SMA iPSCs and MNs. (A) A schematic 
representation of ExSpeU1 targeting the ISS-N1 SMN2 pre-mRNA region. (B–C) iPSCs nucleofected with 
ExSpeU1s-carrying plasmids showed a significant increase in FL SMN expression (SMN-ex7) (p < 0.01) 
that was detected at the protein (B) and mRNA (C) levels with Western blotting and quantitative RT-PCR 
analyses, respectively. (D–F) The motor neuron (MN) differentiation protocol was applied to wild-type 
(WT) iPSCs, HET iPSCs, ExSpeU1-treated SMA iPSCs, and vector control-treated SMA iPSCs. Obtained 
MNs expressed canonical MN markers: SMI32-positive (green) and ChAT-positive (red) cells are both 
expressed, and the cells appear yellow as a result of merged red and green. Nuclei are labeled with DAPI 
(blue). MNs derived from untreated SMA iPSC cultures appeared smaller and sparser than MNs derived 
from WT and HET iPSCs. Notably, MNs derived from ExSpeU1-treated SMA iPSCs presented a rescue of 
cell density in vitro compared with MNs derived from untreated SMA iPSCs (D). MN quantification at week 
10 of the differentiation protocol showed an increased number of ExSpeU1-treated SMA iPSC-derived MNs 
compared with control-treated SMA iPSC-derived MNs (*p < 0.001) (E). Values represent means ± s.e.m. 
from five independent experiments performed in triplicate. Accordingly, MNs derived from ExSpeU1-treated 
SMA iPSCs presented a significant increase in gem number compared with untreated SMA iPSC-derived 
MNs (*p < 0.01) (F). Gem counts in WT and heterozygous (HET) cells are shown for comparison. Values 
represent means ± s.e.m. from five independent experiments performed in triplicate. Scale bar: 75 μ m.
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may contribute to the implementation of knowledge about the pathogenic mechanisms of SMA and the 
selectivity of MN loss in the context of SMN protein depletion. We observed that SMA MNs exhibit spe-
cific disease alterations secondary to the SMN defect, including a reduction in mean survival. These data 
were consistent with our previous results14. We concluded that our SMA model is able to recapitulate at 
least some aspects of the human disease, and may be useful for potential drug screening. Thus, we used 
our iPSC in vitro model of SMA to test novel RNA-based therapeutic strategies.
Researchers have focused on developing SMA therapies for several years. Various strategies have 
been investigated, mainly to directly upregulate or stabilize SMN2 RNA and protein levels3. Given that 
SMN2 is able to produce a small amount of full-length SMN protein through alternative splicing, one 
possible strategy is to target SMN2 to increase SMN protein production. With this purpose, we applied 
three different molecular strategies (MOs, ExSpeU1, and TALE-TF) to induce RNA modifications in 
iPSCs and MNs by modifying ISS-N1, modulating the exon-intron splicing region in SMN2 exon 7, or 
activating SMN2 transcription. These three methods are specific, overcome the limits of exogenous gene 
introduction, and are applicable to other human genetic diseases. Here, we demonstrated that three cor-
rective RNA approaches increase SMN protein and rescue neuropathological features of SMA in MNs.
Figure 5. SMN upregulation in SMA iPSCs using TALE-TFs. (A) A schematic representation of the 
interaction of a TALE-TF construct with SMN2 promoter. (B–D) TALE-TFs increased the transcription 
of the SMN2 gene in SMA iPSCs. Quantitative RT-PCR analysis on SMA iPSCs treated with various 
TALE-TF combinations demonstrated the transcriptional activation of the SMN2 gene in both the 
FL SMN and the SMNΔ 7 transcripts, and highlighted that TALE-TF combination 1 + 3 + 5 was the 
most effective of all tested combinations (*p < 0.01) (B). Accordingly, the immunocytochemistry assay 
documented a higher level of SMN protein expression (green) in SMA iPSCs transfected with TALE-TF 
combination 1 + 3 + 5 than in mock-transfected SMA iPSCs (C). Nuclei are labeled with DAPI (blue). 
TALE-TF-treated cells were more brightly fluorescent than mock-treated cells (*p < 0.01) in quantitative 
analysis (D). Values represent means ± s.e.m. from five independent experiments performed in triplicate. 
Scale bar: 75 μ m.
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The first approach that we tested in our iPSC model was ASO with MO chemistry. ASO technology 
has enabled us (and others) to restore SMN expression in SMA mice, often achieving complete rescue of 
disease phenotype in in vivo models3. MOs targeting SMN2 were active and well tolerated, with impres-
sive results in SMA mice3,11. Our current in vitro results confirm and extend previous data, indicating 
the excellent efficacy of MOs in redirecting SMN2 splicing, thus improving the SMA disease phenotype 
at molecular and cellular levels in human cells. Our findings confirm that iPSCs and MNs can effectively 
screen oligonucleotides or other splicing approaches quickly and cost-effectively in a human-relevant 
model.
The most common ASO chemistries currently used to modify the splicing of SMN2 are phospho-
rothioate oligonucleotides and similar variants (e.g., 2′ -O-methyl phosphorothioate, 2OMePS), which 
have yielded encouraging results in preclinical studies and clinical3. A phase 3 clinical trial in SMA type 
I and type II-III patients with phosphorothiorate oligonucleotides is ongoing (www.clinicaltrial.gov). 
However, their therapeutic application can be limited because of toxicity at higher doses21. In contrast, 
the MO backbone is demonstrably effective and well tolerated, with no drug-related adverse effects in 
completed clinical trials in which an MO was administered systemically at a relatively high dose to boys 
with Duchenne Muscular Dystrophy22. MO stability can allow better efficacy in vivo22.
A great advantage of RNA therapy in SMA compared with other approaches (such as gene therapy) 
is that the SMN2 gene remains expressed under its own endogenous promoter, subject to its regular 
turnover, thus obviating the need for transgene introduction. Disadvantages of potential ASO therapy 
for SMA in humans include the likelihood of relatively invasive delivery methods, such as continuous 
infusion through an implantable intrathecal or intraventricular catheter, or multi-dose bolus injection. 
The exact biodistribution of MO into the CNS after intrathecal injection has yet to be defined. However, 
this approach has an excellent safety profile, and suspending the treatment can reverse its effect.
ExSpeU1 and TALE-TF strategies to modulate SMN2 splicing and expression represent valid alter-
natives to MOs and other ASOs as novel treatments for SMA. These methods can permanently correct 
the defect (like gene therapy) without introducing an exogenous gene, and are regulated by physiological 
promoter sequences (like ASOs). In fact, ExSpeU1 and TALE-TF sequences can be transferred in vivo 
with adenoviral-associated vectors (AAV) such as serotype 9, a vector that can cross the blood brain 
barrier and transfect the CNS safely and effectively3.
We also tested ExSpeU1s as a novel strategy to correct natural splicing defects in SMA, following 
promising results from our previous work18. The SMN2 gene is a classic model of exon skipping caused 
by a synonymous nucleotide variant in an exonic regulatory sequence, and its modulation forms the 
basis for several therapeutic strategies under development for SMA, as mentioned above3. Nevertheless, 
ExSpeU1s have not been widely investigated in SMA.
Few studies have investigated the role of U1 snRNAs in the splicing correction of donor site muta-
tions, or its potential therapeutic effect23. In these experiments, the modified tails of U1 snRNAs have few 
nucleotide modifications compared with wild-type sequences, and match the mutant donor sites exactly. 
Therefore, their action is limited to each mutation, and their possible binding to other normal 5′ splice 
sites might negatively modify the splicing of other alternatively spliced exons.
The ExSpeU1s tested in this study, which link non-conserved intronic SMN2 sequences, do not 
interact directly with normal 5′ splice sites. Our results showed that ExSpeU1s targeting the intronic 
sequences downstream of SMN2 exon 7 rescued correct splicing and recovered the corresponding SMN 
protein biosynthesis in affected MNs. The level of functional SMN obtained may therapeutically correct 
the SMA phenotype, making ExSpeU1s a promising strategy that must be explored in detail.
In vivo, SMN2 splicing correction with ExSpeU1s carried by AAV9 may warrant exploration regard-
ing classical gene replacement, because endogenous SMN2 can be corrected permanently within the 
physiological gene expression provided by the chromosomal context and tissue-specific factors controlled 
through the regulation of transcription and pre-mRNA processing. Another advantage is that U1 snR-
NAs are naturally exported to the nucleus to target pre-mRNAs, ensuring more efficient delivery com-
pared with ASOs. Furthermore, ExSpeU1s can enable permanent correction. It follows that proper vector 
delivery of U1 snRNAs would require few doses, possibly only one. Non-human primate data indicates 
that AAV9 is well distributed after intrathecal injection, compared with oligonucleotides24. We conclude 
TALE-TF target ID Sequence
TALE-TF target 1 TAAGCAACATGCCGAAACCC
TALE-TF target 2 TATAACACAGTGAAATGAAA
TALE-TF target 3 TTGAGAGAAATGAAAAATAT
TALE-TF target 4 TGTGGGAGGGCGATAACCAC
TALE-TF target 5 TCGTAGAAAGCGTGAGAAGT
Table 2.  TALE-TF sequences.
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that ExSpeU1s constitutes a useful new strategy to potentially correct splicing abnormalities linked with 
defective exon definition in SMA and in many other human disorders18.
After testing the beneficial effects of MOs and ExSpeU1s in correcting SMN2 exon 7 splicing, we eval-
uated the possibility of activating SMN2 transcription using TALE-TF technology. Direct activation of 
SMN2 has great potential to facilitate the expression of full-length SMN protein in somatic cells, offering 
the opportunity to improve the current strategy for targeting this gene. The recent advent of engineered 
TALE-TF has opened new avenues for manipulating SMN2 transcription by directly targeting its pro-
moter, and thus has the potential to increase the full-length transcription of SMN2 at a clinically mean-
ingful level. Transcription activator-like (TAL) effectors are proteins produced by Xanthomonas bacteria 
when they infect plants. They enhance gene expression by binding host plant promoters. TAL effectors 
have been employed to generate site-specific gene-editing instruments by fusing target sequence-specific 
TAL effectors to nucleases (TALENs) or transcription factors (TALE-TFs). These proteins can identify 
and link specific target sequences and promote gene editing, including gene knockout, knock-in (with 
donor plasmid), and other effects.
We investigated different TALE-TFs that target a broad range of sequences in the SMN2 promoter. 
The ability of TALE-TFs to interact with endogenous genomic loci is dependent on chromatin state, 
as well as on undefined events that regulate TALE DNA binding19. For these reasons, we tested sev-
eral combinations of TALE-TFs for the SMN2 genomic locus we aimed to target. Using a quantitative 
RT-PCR assay, we identified the highly effective TALE-TFs 1, 3, and 5, which were designed to target the 
human SMN2 promoter. Employing an optimized TALE code and combinations of multiple TALE-TFs, 
we demonstrated that transcription of the endogenous SMN2 gene approximately doubled in treated 
samples. For the first time, we demonstrated conclusively that TALE-TFs targeting the SMN2 promoter 
can facilitate site-specific transcriptional modulation in SMA pathology and can robustly increase endog-
enous SMN2 mRNA.
This is the first study to demonstrate that the activation of endogenous SMN2 by multiple TALE-TFs 
is able to produce mature SMN protein, giving further proof that simultaneous use of engineered 
transcription activator factors is an efficacious strategy for controlling gene expression. The combined 
employment of multiple TFs for endogenous gene activation can avoid the potential off-target effect that 
might be produced by employing single activators19. TALE methodology opens a new field of research, 
which could be used to advance TALE proteins to treat SMA and other human diseases by inducing 
the expression of specific genes. TALEs are theoretically able to target any sequence and have already 
been deployed in many organisms with impressive success19. In the future, clustered regularly inter-
spaced short palindromic repeats/Cas9 transcription factors (CRISPR9-TFs) can be used as an alterna-
tive approach to TALE-TFs, offering another powerful and precise strategy for modulating SMN2 gene 
expression25. Therapeutic sequences from TALE-TFs and CRISPR9-TFs can be transferred in vivo with 
AAV9, as discussed regarding ExSpeU1.
In line with their known different molecular mechanism, the three approaches we have evaluated 
induced up-regulation of full-length SMN mRNA and protein but differentially affect the Delta-7 iso-
form. ASO acts mainly on splice site selection; accordingly, the increase of mRNA including exon 7 
is reflected by a reduction of the shorter isoform that lacks this exon. TALE-TFs are transcriptional 
activators, and the resulting increased SMN2 transcription levels do not affect splice site selection. In 
contrast, ExSpeU1 acting on SMN2 pre-mRNA processing improves both splicing and the total amount 
of SMN transcript17, resulting in increases in both SMN2-derived isoforms. We observed this effect in 
cultured cells17 and in ExSpeU1-treated MN; it might have an additional positive effect in vivo. In fact, 
increased expression of the Delta-7 isoform clearly improves the SMA phenotype26, likely due to residual 
functional activity27. However, the practical clinical implications of this differential proportion between 
the full-length and delta-7 isoforms are unknown. Overall, in this study we successfully achieved SMN2 
targeting with three different RNA approaches in a meaningful experimental human model. Our findings 
may help to develop effective therapies for SMA and other genetic neurological diseases.
Materials and Methods
Viral reprogramming of human somatic cells. The Systembio-Euroclone custom service was 
employed for retroviral reprogramming. Retroviruses carrying OCT4, SOX2, KLF4, and c-MYC were 
added to human fibroblasts (at multiplicity of infection = 5) in 6-well plate. One day after infection, 
the viral supernatant was removed and medium added. On the same day, 1 × 106 mitomycin C-treated 
or irradiated MEF cells were plated (pre-coated with 0.1% gelatin) and incubated overnight. Two days 
after the infection, the cells were trypsinized and plated in a 60 mm dish at cell densities of 3 × 104 
to 1 × 105 cells. Two days later, medium was aspirated and replaced with hES medium (DMEM/F12 
containing 20% knockout serum replacement, 2 mM glutamine, 0.1 M nonessential amino acids, 55 μ M 
2-mercaptoethanol, 10 ng/ml bFGF, 50 U penicillin, and 50 μ g/ml streptomycin). The medium was 
changed daily with hES medium. Colony formation was detected after 3–4 weeks; colonies with hES-like 
morphology were picked manually for expansion in hES medium.
Non-viral reprogramming of human somatic cells. Reprogramming of human skin fibroblasts 
with oriP/EBNA1-based episomal vectors, containing OCT4, SOX2, NANOG, LIN28, c-MYC, and KLF4 
cDNA14, was conducted by nucleofection of combinations of episomal plasmids (NHDF kit VPD-1001 
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with U-20 program, Amaxa, Walkersville, MD). After transfection, fibroblasts (1.0 × 106 cells per 
nucleofection) were plated onto three 10-cm dishes with Matrigel (BD Bioscience) in fibroblast medium.
At 4 days post-transfection, we replaced the fibroblast medium with pluripotent stem cell medium 
(mTeSR, Stem Cell Inc.) for 8–10 days. At day 18 after transfection, first colonies with an iPSC-like 
morphology appeared. We stained one of the three 10-cm dishes of reprogramming culture with alkaline 
phosphatase (Millipore) to identify the eventual presence of human iPSC colonies. Between days 25 and 
30, we passed the other two 10-cm dishes to fresh 10-cm Matrigel-covered dishes at a ratio of 1:3. We 
then isolated the iPSC colonies for further analysis. Efficiency of fibroblast reprogramming was approx-
imately three to six colonies per 106 fibroblast cells, in line with previous reports14.
Immunohistochemistry of iPSCs and their derivatives. Cells were fixed in 4% paraformalde-
hyde for 10 min, permeabilized with 0.5% Tween-20 in PBS, and incubated to 0.1% Tween-20 with 
10% horse serum. We exposed the cells to primary antibodies overnight and to secondary antibodies 
for 1 hour (Alexa Fluor, Invitrogen). We employed the following primary antibodies: SSEA-3 (1:100, 
R&D), SSEA-4 (1:500, DSHB), TRA1-60 (1:500, Chemicon), TRA1-81 (1:500, Chemicon), NANOG 
(1:500 Abcam), alpha-fetoprotein (1:500, DAKO), alpha-actinin (1:500 Sigma), alpha smooth muscle 
actin (1:500, Sigma), Desmin (1:100, Novocastra), TuJ1 (1:1000, Sigma), and glial fibrillary acidic protein 
(GFAP, 1:1000, DAKO; 1:500, Sigma). Alkaline phosphatase staining was performed20. For the analysis, 
we used a confocal LEICA LCS2 microscope.
Differentiation of iPSCs into motor neurons. We generated spinal MNs using a multistage differ-
entiation protocol developed for iPSCs14. To produce MNs, iPSCs were plated with neuronal medium 
[DMEM/F12 (Gibco, Invitrogen), supplemented with MEM nonessential amino acids, N2, and heparin 
(2 μ g/mL, Sigma-Aldrich)]. After 10 days, we added retinoic acid (RA) (0.1 μ M, Sigma-Aldrich) for neu-
ral caudalization. At day 17, we collected the posteriorized neuroectodermal cells. These clusters were 
suspended for 1 week in the same medium with RA (0.1 μ M) and sonic hedgehog (SHH) (100–200 ng/
mL, R&D Systems Inc.). On day 24, we supplemented the medium with other growth factors [e.g., 
brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), and insulin-like 
growth factor-1 (IGF1) (10 ng/mL, Peprotech)]. MNs were enriched with gradient centrifugation14.
Motor neuron phenotype analysis. Next, we analyzed the MN phenotype via immunohistochemis-
try14. The following antibodies were used: TuJ1 (1:200, Millipore), GFAP (1:300, SIGMA), OLIG2, (1:500, 
Santa Cruz), ISLET1 (1:200, Millipore), HB9 (1:200 Millipore), ChAT (1:200, Millipore), MAP2 (1:100; 
Sigma), and SMI32 (Covance, 1:500). For phenotypic analysis, the percentage of any given phenotype in 
a sample was obtained by averaging proportions of a specific cell type in each of 10 randomly chosen 
fields. Five independent experiments in triplicate were considered. Morphometric and MN count analy-
sis were performed14. Results are expressed as mean ± s.e.m. for five independent experiments.
MO sequences and cell nucleofection. The MO-10-34 sequence (GTAAGATTCACTTTCATAATG 
CTGG) was synthesized as bare MO11. The Scr-MO sequence (GTAACATTGACTTTGATATTCCTGG) 
was used as control (www.gene-tools.com). iPSCs or MNs were transfected with nucleofection. The cell 
pellet was resuspended in 100 μ L Resuspension Buffer (Life Technologies). Twenty micrograms MO were 
added to the cells and mixed by vortexing. Each sample was transferred to a nucleofection cuvette and 
transfected using Neon System (Life Technologies). After nucleofection, the samples were transferred 
from the Neon Tip into the prepared culture plates containing pre-warmed medium. The cells were 
harvested at different time points after nucleofection (24, 48, and 72 hours; and 5–7 days).
ExSpeU1 sequences and nucleofection. We have previously described vector and sequence encod-
ing ExSpeU1s for SMN2 (sm17) and control vectors17. We used both minigene and plasmids with hygro-
mycin selection. After the centrifugation enrichment, iPSCs or MNs were transfected with nucleofection. 
The cell pellet was resuspended in 100 μ L Resuspension Buffer (Life Technologies) per manufacturer’s 
direction. ExSpeU1 plasmids (5 μ g) were added to the cells and mixed by vortexing. Each sample was 
transferred to a nucleofection cuvette and transfected using Neon System (Life Technologies). After 
nucleofection, the samples were transferred from the Neon Tip into the prepared culture plates con-
taining pre-warmed medium. The cells were harvested at different time points after nucleofection (24, 
48, 72 hours; and 5–7 days). We selected iPSC clones with hygromycin and cells that steadily expressed 
ExSpeU1 into MNs.
TALE-TF sequences and transfection. Five TALE-TF constructs targeting the SMN2 sequence 
were custom-generated by GeneCopoeia (Table 2). GeneCopoeia control vector was also employed. For 
plasmid transfection, ~100,000–300,000 cells/well were plated in a 6-well plate according to the manu-
facturer’s recommendation. On the day before transfection, we trypsinized and counted the cells. The 
number of cells plated per well was determined so that they reached 70–80% confluence at the time of 
transfection. The next day, we prepared transfection complexes of TALE-TFs using via fect transfection 
reagent transfection reagent according to the manufacturer’s instructions (3 μ g TALE-TF plasmids). The 
cells were harvested at different time points after nucleofection (24, 48, 72 hours; and 5–7 days).
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RNA isolation, quantitative RT-PCR and RT-PCR. Total RNA was isolated from cells using the 
RNeasy Mini Kit (Qiagen) following the manufacturer’s protocol. Concentrations were detected with a 
Nanodrop spectrophotometer. Only samples with ratios between 1.8 and 2.0 were employed. For mRNA 
analyses, 1 μ g of total RNA was reverse-transcribed using the Ready-To-Go kit (GE Healthcare) accord-
ing to the manufacturer’s protocol. Reverse-transcribed material corresponding to 15 ng RNA was ampli-
fied with TaqMan Universal PCR Master Mix (Applied Biosystem) and the appropriate primers following 
the method described28 (600 nM each) in 7500 Real Time PCR System (Applied Biosystem). RT-PCR was 
carried out with a set of primer that spans the region from the exon 5–6 junction and exon 8 (forward 
5′ CTTCTGGACCACCAATAATTCC3′ ; reverse 5′ AAGAGTTACCCATTCCACTTC3′ ). PCR products 
were separated on a 2% agarose gel and densitometric analysis was performed with Image J software.
Western blot assay. Cells were washed with PBS and detached by scraping. Pellets were sonicated 
on ice for 10 min in buffer supplemented with protease and phosphatase inhibitor cocktail (Pierce) 
as described14. The lysates were centrifugated at 13,500 rpm for 10 min at 4 °C. Protein concentration 
was quantified by the Bradford assay (Pierce). Twenty micrograms of proteins were separated by 12% 
SDS-PAGE and electrophoretically transferred to a nitrocellulose membrane. Membranes were incubated 
with the antibodies against SMN (1:1.000 BD) and actin (1:1000, Sigma). Next, membranes were probed 
with secondary peroxidase-conjugated antibody (Invitrogen), and proteins were revealed with chemilu-
minescence assay (Amersham). Densitometric analysis was carried out using Image J software.
Immunocytochemistry and gems analysis. This study was performed as previously described14. 
The cells seeded in slides were washed with PBS and fixed with 1:1 acetone:methanol for 5 min. Then 
they were incubated with a solution of 10%BSA, 2%Triton in PBS. After washing cells were probed with 
an antibody against SMN in 3% BSA for 1 hour (1:100, BD). Cells were washed with PBS and incubated 
for 1 hour with secondary antibodies (Alexa Fluor, Invitrogen). After further washes with PBS, the slides 
were mounted with DAPI (Invitrogen). Cells were analyzed using an SP2 AOBS confocal microscope. 
The gems number was quantified with previously reported protocol14. Two independent observers exam-
ined at least 100 cells in randomly selected fields from each slide, and recoded the gems number and the 
percent of cells with gem-positive nuclei in the different treatments.
Statistical analysis. Stats Direct software was used for all statistical analyses. All counting data 
from immunocytochemical analyses and cell survival were expressed as mean values ± S.D or s.e.m. 
Differences between two means were analyzed using Student’s t-test (two-tailed), and differences among 
more than two means were analyzed using one- or two-way ANOVA. When ANOVA showed significant 
differences, pair-wise comparisons between means was performed using Tukey’s post-hoc test. In all 
analyses, the significance threshold was defined as p-value ≤ 0.05.
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